User login
Key clinical point: A strict approach toward treat-to-target (T2T) management did not reduce radiographic progression in a daily practice cohort of patients with active rheumatoid arthritis (RA) compared with a relatively lenient approach toward T2T.
Major finding: A T2T approach in a 3-month interval failed to reduce radiographic progression in the same 6-month period with 2 vs 0 visits (change in Sharp-van der Heijde score [Δ] 0.15 units; 95% CI −0.04 to 0.33) and 1 vs 0 visits (Δ 0.08 units; 95% CI −0.06 to 0.22) after T2T.
Study details: This longitudinal analysis of a 2-year prospective observational study cohort included 521 patients with active RA who started or changed conventional synthetic or biologic disease-modifying antirheumatic drugs and underwent treatment intensification according to the T2T approach.
Disclosures: The BIODAM study was supported by an unrestricted grant from AbbVie. Several authors reported receiving research grants, consulting fees, honoraria, or an unrestricted educational grant from various sources, including AbbVie.
Source: Ramiro S et al. Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM. Rheumatology (Oxford). 2023 (Jan 16). Doi:10.1093/rheumatology/kead021
Key clinical point: A strict approach toward treat-to-target (T2T) management did not reduce radiographic progression in a daily practice cohort of patients with active rheumatoid arthritis (RA) compared with a relatively lenient approach toward T2T.
Major finding: A T2T approach in a 3-month interval failed to reduce radiographic progression in the same 6-month period with 2 vs 0 visits (change in Sharp-van der Heijde score [Δ] 0.15 units; 95% CI −0.04 to 0.33) and 1 vs 0 visits (Δ 0.08 units; 95% CI −0.06 to 0.22) after T2T.
Study details: This longitudinal analysis of a 2-year prospective observational study cohort included 521 patients with active RA who started or changed conventional synthetic or biologic disease-modifying antirheumatic drugs and underwent treatment intensification according to the T2T approach.
Disclosures: The BIODAM study was supported by an unrestricted grant from AbbVie. Several authors reported receiving research grants, consulting fees, honoraria, or an unrestricted educational grant from various sources, including AbbVie.
Source: Ramiro S et al. Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM. Rheumatology (Oxford). 2023 (Jan 16). Doi:10.1093/rheumatology/kead021
Key clinical point: A strict approach toward treat-to-target (T2T) management did not reduce radiographic progression in a daily practice cohort of patients with active rheumatoid arthritis (RA) compared with a relatively lenient approach toward T2T.
Major finding: A T2T approach in a 3-month interval failed to reduce radiographic progression in the same 6-month period with 2 vs 0 visits (change in Sharp-van der Heijde score [Δ] 0.15 units; 95% CI −0.04 to 0.33) and 1 vs 0 visits (Δ 0.08 units; 95% CI −0.06 to 0.22) after T2T.
Study details: This longitudinal analysis of a 2-year prospective observational study cohort included 521 patients with active RA who started or changed conventional synthetic or biologic disease-modifying antirheumatic drugs and underwent treatment intensification according to the T2T approach.
Disclosures: The BIODAM study was supported by an unrestricted grant from AbbVie. Several authors reported receiving research grants, consulting fees, honoraria, or an unrestricted educational grant from various sources, including AbbVie.
Source: Ramiro S et al. Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM. Rheumatology (Oxford). 2023 (Jan 16). Doi:10.1093/rheumatology/kead021